The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
D 1 and D 2 Dopamine Receptor-regulated Gene Expression of Striatonigral and Striatopallidal Neurons
Gerfen, C. R., Engber, T. M., Mahan, L. C., Susel, Z., Chase, T. N., Monsma, F. J., & Sibley, D. R. (1990) · Science · doi:10.1126/science.2147780 · Cited by 2,967
Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., & Kopin, I. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4546 · Cited by 2,149
Modification of Parkinsonism — Chronic Treatment with L-Dopa
Cotzias, G. C., Papavasiliou, P. S., & Gellene, R. (1969) · New England Journal of Medicine · doi:10.1056/nejm196902132800701 · Cited by 1,284
Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors
Baik, J.-H., Picetti, R., Saiardi, A., Thiriet, G., Dierich, A., Depaulis, A., Le Meur, M., & Borrelli, E. (1995) · Nature · doi:10.1038/377424a0 · Cited by 650
BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization
Guillin, O., Diaz, J., Carroll, P., Griffon, N., Schwartz, J.-C., & Sokoloff, P. (2001) · Nature · doi:10.1038/35075076 · Cited by 574
Self-citationSelective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist
Pilla, M., Perachon, S., Sautel, F., Garrido, F., Mann, A., Wermuth, C. G., Schwartz, J.-C., Everitt, B. J., & Sokoloff, P. (1999) · Nature · doi:10.1038/22560 · Cited by 565
Self-citationPathophysiology of levodopa-induced dyskinesia: Potential for new therapies
Bezard, E., Brotchie, J. M., & Gross, C. E. (2001) · Nature Reviews Neuroscience · doi:10.1038/35086062 · Cited by 503
Self-citationBezard, E., Dovero, S., Prunier, C., Ravenscroft, P., Chalon, S., Guilloteau, D., Crossman, A. R., Bioulac, B., Brotchie, J. M., & Gross, C. E. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-17-06853.2001 · Cited by 483
Self-citationA targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice.
Accili, D., Fishburn, C. S., Drago, J., Steiner, H., Lachowicz, J. E., Park, B. H., Gauda, E. B., Lee, E. J., Cool, M. H., Sibley, D. R., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.5.1945 · Cited by 468
Sokoloff, P., Andrieux, M., Besançon, R., Pilon, C., Martres, M.-P., Giros, B., & Schwartz, J.-C. (1992) · European Journal of Pharmacology: Molecular Pharmacology · doi:10.1016/0922-4106(92)90107-7 · Cited by 400
Self-citationInduction of dopamine D 3 receptor expression as a mechanism of behavioral sensitization to levodopa
Bordet, R., Ridray, S., Carboni, S., Diaz, J., Sokoloff, P., & Schwartz, J.-C. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.7.3363 · Cited by 345
Self-citationReavill, C., Taylor, S. G., Wood, M. D., Ashmeade, T., Austin, N. E., Avenell, K. Y., Boyfield, I., Branch, C. L., Cilia, J., Coldwell, M. C., et al. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39184-0 · Cited by 287
Gurevich, E. V. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830150047009 · Cited by 248
D3 dopamine receptor mRNA is widely expressed in the human brain
Suzuki, M., Hurd, Y. L., Sokoloff, P., Schwartz, J.-C., & Sedvall, G. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01078-0 · Cited by 232
Self-citationA Paradigm Shift in Brain Research
Carlsson, A. (2001) · Science · doi:10.1126/science.1066969 · Cited by 221
Pearce, R. K. B., Jackson, M., Smith, L., Jenner, P., & Marsden, C. D. (1995) · Movement Disorders · doi:10.1002/mds.870100606 · Cited by 218
Neuromodulatory actions of dopamine on synaptically-evoked neostriatal responses in slices
Levine, M. S., Li, Z., Cepeda, C., Cromwell, H. C., & Altemus, K. L. (1996) · Synapse · doi:10.1002/(sici)1098-2396(199609)24:1<60::aid-syn7>3.0.co;2-e · Cited by 200
Boraud, T., Bezard, E., Bioulac, B., & Gross, C. E. (2001) · Brain · doi:10.1093/brain/124.3.546 · Cited by 193
Self-citationLévesque, D., Martres, M. P., Diaz, J., Griffon, N., Lammers, C. H., Sokoloff, P., & Schwartz, J. C. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1719 · Cited by 180
Self-citationNafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents.
Sautel, F., Griffon, N., Sokoloff, P., Schwartz, J. C., Launay, C., Simon, P., Costentin, J., Schoenfelder, A., Garrido, F., & Mann, A. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12176-9 · Cited by 164
Self-citationImbert, C., Bézard, E., Guitraud, S., Boraud, T., & Gross, C. E. (2000) · Journal of Neuroscience Methods · doi:10.1016/s0165-0270(99)00184-3 · Cited by 163
Self-citationHornykiewicz, O. (1963) · PubMed · Cited by 148
Pilon, C., Lévesque, D., Dimitriadou, V., Griffon, N., Martres, M., Schwartz, J., & Sokoloff, P. (1994) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(94)90182-1 · Cited by 122
Self-citationMillan, M. J., Gobert, A., Newman‐Tancredi, A., Lejeune, F., Cussac, D., Rivet, J., Audinot, V., Dubuffet, T., & Lavielle, G. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39332-2 · Cited by 122
Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease
Ryoo, H., Pierrotti, D., & Joyce, J. N. (1998) · Movement Disorders · doi:10.1002/mds.870130506 · Cited by 112
Morissette, M., Goulet, M., Grondin, R., Blanchet, P. J., Bédard, P. J., Paolo, T. D., & Lévesque, D. (1998) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1998.00264.x · Cited by 109
Noradrenoceptor antagonism with idazoxan improves l-dopa-induced dyskinesias in MPTP monkeys
Grondin, R., Tahar, A. H., Doan, V. D., Ladure, P., & Bédard, P. J. (2000) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s002109900167 · Cited by 91
Pharmacology of dopamine agonists in the treatment of Parkinson’s disease
Jenner, P. G. (2002) · Neurology · doi:10.1212/wnl.58.suppl_1.s1 · Cited by 91
Quik, M., Police, S. M. C., He, L., Monte, D. A. D., & Langston, J. W. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00130-5 · Cited by 73
Being partial to psychostimulant addiction therapy
Pulvirenti, L., & Koob, G. F. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01991-x · Cited by 27
Solano (2000) · doi:10.1002/1531-8249(200002)47:2 · Cited by 3
Cited by
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Duty, S., & Jenner, P. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01426.x · Cited by 753
Toxin-induced models of Parkinson’s disease
Bové, J., Prou, D., Perier, C., & Przedborski, S. (2005) · NeuroRX · doi:10.1602/neurorx.2.3.484 · Cited by 739
G Protein–Coupled Receptor Oligomerization Revisited: Functional and Pharmacological Perspectives
Ferré, S., Casadó, V., Devi, L. A., Filizola, M., Jockers, R., Lohse, M. J., Milligan, G., Pin, J.-P., & Guitart, X. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008052 · Cited by 570
Olanow, C. W., Obeso, J. A., & Stocchi, F. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70521-x · Cited by 547
Metadata
- Authors
- Bézard, E., Ferry, S., Mach, U., Stark, H., Leriche, L., Boraud, T., Gross, C., & Sokoloff, P.
- Venue
- Nature Medicine
- Published
- 2003-05-12
- Volume
- 9
- Issue
- 6
- Pages
- 762-767
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1981821582
- Cited by
- 383
- References
- 31
- FWCI
- 16.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.